Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Immunome, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
IMNM
Nasdaq
2836
immunome.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Immunome, Inc.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Feb 6th, 2025 9:01 pm
Insider Stock Buying Reaches US$2.82m On Immunome
- Feb 4th, 2025 12:54 pm
Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Jan 31st, 2025 9:01 pm
Immunome Announces Pricing of Upsized Public Offering of Common Stock
- Jan 30th, 2025 4:11 am
Immunome Announces Proposed Public Offering of Common Stock
- Jan 29th, 2025 9:27 pm
Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
- Jan 13th, 2025 1:00 pm
Hummingbird Bioscience Licenses Novel Antibodies to Immunome
- Jan 7th, 2025 1:00 pm
Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference
- Nov 27th, 2024 1:00 pm
Immunome Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
- Nov 15th, 2024 11:28 am
Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates
- Nov 13th, 2024 10:15 pm
Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update
- Nov 13th, 2024 9:05 pm
ImmunityBio (IBRX) Reports Q3 Loss, Tops Revenue Estimates
- Nov 12th, 2024 1:40 pm
Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference
- Nov 5th, 2024 1:00 pm
Immunome Advances with Strategic Asset Acquisition and Agreement
- Oct 30th, 2024 12:30 pm
Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021
- Oct 29th, 2024 12:00 pm
Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium
- Oct 18th, 2024 12:00 pm
Immunome Appoints Roee Shahar as Executive Vice President, Commercial
- Oct 8th, 2024 12:05 pm
Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
- Sep 13th, 2024 11:00 am
Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
- Aug 29th, 2024 12:00 pm
Immunome Stock Sees RS Rating Jump To 91
- Aug 20th, 2024 7:26 pm
Scroll